– Total revenue of $6.2 million for the second quarter 2022 –
– Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the end of 2022 –
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
– Total revenue of $6.2 million for the second quarter 2022 –
– Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the end of 2022 –
Read more at globenewswire.com